News related to Nexavar (Sorafenib) and/or conditions it is approved for
FDA approves Nexavar to treat type of thyroid cancer
Source: Endocrinology News From Medical News Today [2013.11.26]
The U.S. Food and Drug Administration has expanded the approved uses of Nexavar (sorafenib) to treat late-stage (metastatic) differentiated thyroid cancer. Thyroid cancer is a cancerous growth of the thyroid gland, which is located in the neck. Differentiated thyroid cancer is the most common type of thyroid cancer.
Nexavar Approval Expanded for Common Thyroid Cancer
Source: MedicineNet Diarrhea Specialty [2013.11.25]
Title: Nexavar Approval Expanded for Common Thyroid Cancer
Category: Health News
Created: 11/22/2013 5:36:00 PM
Last Editorial Review: 11/25/2013 12:00:00 AM
Targeted Tx Fails 2 Tests in Metastatic Renal Cancer
Source: MedPage Today Oncology/Hematology [2013.12.04]
(MedPage Today) -- A mammalian target of rapamycin (mTOR) inhibitor failed to improve outcomes in metastatic renal cell carcinoma (RCC) as compared with other therapeutic options, according to two randomized trials.
Predicting outcome for cancer patients receiving high-dose IL-2 therapy
Source: Urology / Nephrology News From Medical News Today [2013.12.03]
One of the most potent forms of immunotherapy for patients with metastatic melanoma and renal cell carcinoma is high-dose (HD) bolus IL-2 therapy. Approximately 15% of patients respond to HD IL-2 therapy, with almost 5% going into complete remission; however, use of HD IL-2 therapy is limited due to the toxic effects associated with treatment.